XOMAXOMA Corporation
40.17USD0.00%Mkt Cap: 710.16M $P/E: 25.5934d ago
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty paymen…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m... | ||